A Phase 2, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Study of GS-4997 in Subjects With Pulmonary Arterial Hypertension
Phase of Trial: Phase II
Latest Information Update: 12 May 2017
At a glance
- Drugs Selonsertib (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Acronyms ARROW
- Sponsors Gilead Sciences
- 07 Jun 2017 Biomarkers information updated
- 07 Jan 2017 This trial was discontinued in Germany, according to European Clinical Trials Database.
- 21 Dec 2016 Status changed from active, no longer recruiting to completed.